PolyPid Ltd. (NASDAQ:PYPD) Given Average Rating of "Moderate Buy" by Analysts

Key Points

• PolyPid Ltd. has received a consensus recommendation of "Moderate Buy" from analysts, with one sell rating, five buy ratings, and one strong buy rating among the seven firms covering the stock.
• The average target price projected by analysts for PolyPid shares is $12.40, indicating potential upside from the current trading price of approximately $3.27.
• The company reported an earnings per share of ($0.78), missing consensus estimates by $0.25, highlighting ongoing financial challenges despite its developmental progress.

Shares of PolyPid Ltd. (NASDAQ:PYPD - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the seven ratings firms that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, five have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $12.40.

Several analysts have weighed in on the stock. Roth Capital reiterated a "buy" rating on shares of PolyPid in a research note on Thursday, August 14th. HC Wainwright reiterated a "buy" rating and issued a $13.00 price objective on shares of PolyPid in a research note on Wednesday, August 13th. Craig Hallum reiterated a "buy" rating and issued a $13.00 price objective (down previously from $15.00) on shares of PolyPid in a research note on Thursday, August 14th. Wall Street Zen upgraded shares of PolyPid from a "sell" rating to a "hold" rating in a research note on Friday, September 26th. Finally, Weiss Ratings reiterated a "sell (e+)" rating on shares of PolyPid in a research note on Wednesday, October 8th.

Hedge Funds Weigh In On PolyPid

A hedge fund recently bought a new stake in PolyPid stock. Lumbard & Kellner LLC bought a new stake in PolyPid Ltd. (NASDAQ:PYPD - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm bought 38,200 shares of the company's stock, valued at approximately $135,000. Lumbard & Kellner LLC owned 0.24% of PolyPid as of its most recent SEC filing. Institutional investors and hedge funds own 26.47% of the company's stock.

PolyPid Stock Performance

NASDAQ PYPD opened at $3.27 on Monday. The firm has a 50-day moving average of $3.41 and a 200-day moving average of $3.22. The stock has a market cap of $51.99 million, a PE ratio of -0.85 and a beta of 1.50. PolyPid has a 52-week low of $2.30 and a 52-week high of $3.93.

PolyPid (NASDAQ:PYPD - Get Free Report) last posted its earnings results on Wednesday, August 13th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.53) by ($0.25). As a group, analysts predict that PolyPid will post -1.79 EPS for the current fiscal year.

About PolyPid

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.